8-K: ABVC BioPharma Licenses NSCLC Treatment to OncoX, Anticipates $13.75M Income and Royalties

ABVC BioPharma has granted OncoX exclusive rights to develop and commercialize its Maitake Mushroom extract for Non-Small Cell Lung Cancer in North America, expecting $13.75 million in income and potential royalties.

Summary

• ABVC BioPharma and its affiliate Rgene Corporation have entered into a licensing agreement with OncoX BioPharma for the development and commercialization of ABVC's botanical drug extract, BLEX 404, derived from Maitake mushrooms, for the treatment of Non-Small Cell Lung Cancer (NSCLC) in North America.
• OncoX will have exclusive rights for 20 years to develop and commercialize the product in North America.
• ABVC and Rgene will receive an upfront payment of $6,250,000 each, totaling $12,500,000, either in cash or OncoX shares, within 30 days of the agreement.
• An additional milestone payment of $625,000 each, totaling $1,250,000, is due 30 days after OncoX completes its next round of fundraising, though this is not guaranteed.
• ABVC and Rgene are also entitled to 5% royalties on net sales of the licensed product, up to a total of $6,250,000 each, totaling $12,500,000.
• The total potential income from the agreement is $13.75 million plus up to $12.5 million in royalties.
• ABVC will be responsible for the clinical development of the Licensed Product outside of North America and will supply the product to OncoX for clinical studies in North America.
• OncoX will be responsible for regulatory filings and commercialization of the product in North America.
• The agreement also includes technology sharing and intellectual property rights provisions.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the significant licensing agreement, potential revenue streams, and the collaboration between two companies. The potential for a new treatment for NSCLC is also a positive factor. However, the uncertainty of the milestone payment and the dependence on OncoX's success temper the overall sentiment slightly.

Positives

• The licensing agreement provides a significant upfront payment of $12.5 million to ABVC.
• There is potential for an additional $1.25 million milestone payment.
• ABVC will receive 5% royalties on net sales, up to $12.5 million, providing a long-term revenue stream.
• The agreement allows ABVC to focus on clinical development outside of North America while OncoX handles commercialization in North America.
• The partnership leverages the strengths of both companies, potentially accelerating the availability of the treatment.
• The agreement covers a 20-year period, providing long-term stability.

Negatives

• The $1.25 million milestone payment is not guaranteed, as it depends on OncoX's future fundraising.
• The royalty payments are dependent on the successful commercialization of the product and may not reach the maximum of $12.5 million.
• The agreement is limited to North America, meaning ABVC will need to find other partners for other regions.
• The manufacturing of the finished product is subject to further negotiation.

Risks

• The success of the licensed product is dependent on OncoX's ability to complete regulatory filings and commercialize the product effectively.
• There is a risk that OncoX may not be able to secure the necessary funding for further development and commercialization.
• The product may not achieve the expected sales targets, impacting the royalty payments.
• There is a risk of delays in the regulatory approval process.
• The agreement is subject to the laws of the United States, which may introduce legal risks.

Future Outlook

The agreement is expected to generate significant revenue for ABVC through upfront payments, milestone payments, and royalties. The success of the product will depend on OncoX's ability to commercialize it effectively in North America. The global cancer therapeutics market is expected to grow significantly, which could benefit the product's sales.

Management Comments

• Dr. Uttam Patil, ABVC's CEO, stated that the collaboration represents a significant step forward in their mission to combat NSCLC and underscores their commitment to delivering innovative therapies.
• Wen-Pin Yen, CEO of OncoX, said that the licensing agreement exemplifies ABVC and OncoX's shared dedication to advancing medical science and improving patient care.

Industry Context

This agreement aligns with the trend of pharmaceutical companies licensing out drug candidates to specialized companies for commercialization. The focus on combination therapies for NSCLC is also a growing trend in the oncology field. The global cancer therapeutics market is expected to grow significantly, which could benefit the product's sales.

Comparison to Industry Standards

• Licensing agreements in the pharmaceutical industry often involve upfront payments, milestone payments, and royalties, similar to this agreement.
• The 5% royalty rate is within the typical range for pharmaceutical licensing agreements, although it can vary based on the stage of development and market potential.
• The 20-year license term is a standard duration for pharmaceutical licenses.
• The agreement structure, with one company focusing on development and another on commercialization, is a common model in the industry.
• The focus on a botanical drug extract is a unique aspect, as most NSCLC treatments are based on synthetic compounds or biologics. This could provide a competitive advantage if the product proves effective.

Stakeholder Impact

• Shareholders of ABVC BioPharma are likely to view this agreement positively due to the potential for increased revenue and growth.
• Patients with NSCLC may benefit from the development of a new treatment option.
• Employees of both ABVC and OncoX may see increased job security and opportunities.
• The agreement may also have a positive impact on the broader healthcare industry by advancing medical science.

Next Steps

• OncoX will proceed with regulatory filings for the licensed product in North America.
• ABVC will continue clinical development of the product outside of North America.
• Both companies will work together to ensure the successful commercialization of the product.
• Further study and analysis are to be performed for the feasibility of the Licensed Product API manufacturing under CMO model.

Key Dates

Keywords

Licensing Agreement, Non-Small Cell Lung Cancer, NSCLC, Maitake Mushroom, BLEX 404, OncoX BioPharma, ABVC BioPharma, Rgene Corporation, Royalties, Pharmaceuticals, Drug Development, Clinical Trials